High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan

Marusawa, Hiroyuki; Osaki, Yukio; Kimura, Toshinari; Itō, Kōji; Yamashita, Yo‐ichi; Eguchi, Takeko; Kudo, Masatoshi; Yamamoto, Yoshihiro; Kojima, Hideo; Seno, Hiroshi; Moriyasu, Fuminori; Chiba, Tsutomu

doi:10.1136/gut.45.2.284

Cited by 77 publications

(84 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Marusawa et al (12) reported that 363 (59.4%) out of 611 HCV-related HCC patients had anti-HBc positivity, and have suggested that HBV infection, including latent infection, plays an important role in carcinogenesis in patients with HCV-related liver disease. Our results were similar to that study, although in terms of HCC recurrence, anti-HBc positivity was not demonstrated to be a prognostic factor.…”

Section: Discussionmentioning

confidence: 99%

“…Serum antibody to hepatitis B core antigen (anti-HBc) positivity, which indicates a past history of HBV infection, has recently been attracting attention as a predictor of liver carcinogenesis in patients with HCV-related liver diseases (8)(9)(10)(11)(12). HBV DNA may be present in a latent form, even after seroclearance of HB surface antigen (HBsAg), which is referred to as occult HBV infection (8,13).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma

et al. 2013

View full text Add to dashboard Cite

Abstract. The impact of antibodies to hepatitis B core antigen (anti-HBc) on survival after curative surgical resection (SR) for hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) remains unclear. The aim of the present study was to examine the relationship between anti-HBc positivity and survival of HCV-related HCC patients who underwent curative SR. A total of 222 patients with HCV-related, hepatitis B surface antigen (HBsAg)-negative HCC who underwent curative SR were analyzed. They included 119 anti-HBcpositive patients (53.6%) and 103 anti-HBc-negative patients (46.4%). Overall survival (OS) and recurrence-free survival (RFS) rates were compared between the two groups. The median follow-up periods in the anti-HBc-positive and antiHBc-negative groups were 3.4 years (range, 0.3-10.9 years) and 3.2 years (range, 0.5-10.9 years), respectively. The 1-, 3-and 5-year cumulative OS rates were 88.8, 70.2 and 50.0%, respectively, in the anti-HBc-positive group and 95.8, 77.1 and 61.7% in the anti-HBc-negative group (P=0.300). The corresponding RFS rates were 68.7, 33.0 and 20.0%, respectively, in the anti-HBc-positive group and 74.4, 38.5 and 16.5% in the anti-HBc-negative group (P=0.482). Multivariate analyses identified serum albumin ≥3.8 g/dl (P=0.005) and the presence of microvascular invasion (P<0.001) as independent factors linked to OS, and interferon therapy after surgery (P=0.011), α-fetoprotein ≥40 ng/ml (P=0.030) and the presence of microvascular invasion (P<0.001) were significant predictors linked to RFS. In subgroup analyses according to maximum tumor size and background liver disease in terms of OS and RFS, no significant difference between the antiHBc-positive and anti-HBc-negative groups was observed except in patients with non-cirrhotic liver in terms of RFS.In conclusion, anti-HBc-positivity is not a useful predictor for survival of patients with HCV-related HCC after curative SR.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Although epidemiologic studies have highlighted the superadditive effect of co-infection with HBV and HCV on increasing the risk for HCC (165,188,189), other studies have reported a subadditive effect on dual infection (32). Similarly, it has been suggested that latent HBV infection plays an important role in carcinogenesis in HCV-infected individuals (190,191). HCV is not directly cytopathic, and the pathogenesis of liver injury is believed to be immune mediated.…”

Section: Hbv and Hcvmentioning

confidence: 99%

Multiple Infections and Cancer: Implications in Epidemiology

Vedham

Divi

Starks

et al. 2014

Technol Cancer Res Treat

View full text Add to dashboard Cite

Approximately 18% of the global cancer burden has been attributed to infectious agents, with estimates ranging from 7% in developed countries to about 22% in developing countries.Chronic infections caused by the hepatitis B and C viruses, human papilloma viruses (HPV), and Helicobacter pylori (H. pylori) are reported to be responsible for approximately 15% of all human cancers. Interestingly, although many of the infectious agents that have been associated with cancer-such as HPV, Epstein-Barr virus (EBV), and H. pylori-are highly prevalent in the world, most infected individuals do not develop cancer but remain lifelong carriers. Malignancies associated with infectious agents may result from prolonged latency as a result of chronic infections. Pathogenic infections are necessary but are not sufficient for cancer initiation or progression. Cancer initiation may require additional cofactors, including secondary infections. Therefore, in patients with chronic infection with one agent, secondary co-infection with another agent may serve as an important co-factor that may cause cancer initiation and progression. Additionally, opportunistic co-infections could significantly inhibit response to cancer treatment and increase cancer mortality. Co-infections are relatively common in areas with a high prevalence of infectious agents, especially in developing countries. These co-infections can cause an imbalance in the host immune system by affecting persistence of and susceptibility to malignant infections. Several articles have been published that focus on infectious agents and cancer. In this article, we discuss the role of infectious agents in malignancies, highlight the role of multiple/co-infections in cancer etiology, and review implications for cancer epidemiology.

show abstract

“…Several studies have shown that anti-HBc positivity was associated with the development of HCC in patients with HCV-associated chronic liver disease (11,(24)(25)(26). However, considering the natural history of all HCV infections, the results of those previous studies have some problems, i.e., the observation period was short and the research was performed in a retrospective manner in patients with chronic hepatitis and liver cirrhosis.…”

Section: Discussionmentioning

confidence: 79%

“…That is, anti-HBc, which was initially considered to be an index for the past HBV infection in which all HBV had been cleared, has emerged as a convincing marker of occult hepatitis B (19,(21)(22)(23). Also, several studies showed that the anti-HBc positivity was associated with the development of HCC in patients with HCV-associated chronic liver disease (11,(24)(25)(26), but these associations have not been clearly demonstrated.…”

Section: Introductionmentioning

confidence: 99%

Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: A 12-year prospective study

Tanaka

Nagao²,

Ide³

et al. 2006

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Several studies have reported that antibody to hepatitis B core antigen (anti-HBc) positivity may influence the development of hepatocellular carcinoma (HCC) in chronic hepatitis C patients, but the evidence is still not conclusive. In this study, we examined whether the presence of antiHBc positive was associated with the development of HCC in hepatitis C virus (HCV)-infected subjects among the residents in an HCV hyperepidemic area who were followed up for 12 years. In an HCV hyperendemic area (positive rate of anti-HCV: 23.4%), 509 residents were examined by health screening in 1990. After 12 years of follow-up, we evaluated the risk factors for HCC. The incidence of HCC was compared between anti-HBc positive and anti-HBc negative subjects after 12 years of prospective observation. Univariate and multivariate analyses were conducted to determine risk factors for the development of HCC. The incidence of HCC was significantly higher in the anti-HBc positive group (13 subjects) than in the anti-HBc negative group (0 subjects) (P=0.012). Multivariate analysis identified positivity for antiHBc and HCV RNA, history of icterus, and female gender as independent determinants of the development of HCC. Our findings provide clear evidence in a prospective study that presence of anti-HBc, that is, past hepatitis B virus (HBV) infection, is a risk factor for the development of HCC in HCVinfected people.

show abstract

High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan

Cited by 77 publications

References 32 publications

Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma

Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma

Multiple Infections and Cancer: Implications in Epidemiology

Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: A 12-year prospective study

Contact Info

Product

Resources

About